Maravai LifeSciences (NASDAQ:MRVI) Sets New 52-Week Low – Should You Sell?

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)’s share price hit a new 52-week low on Tuesday . The company traded as low as $3.91 and last traded at $4.01, with a volume of 3330920 shares traded. The stock had previously closed at $4.11.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Guggenheim started coverage on shares of Maravai LifeSciences in a research note on Thursday, December 19th. They set a “neutral” rating on the stock. William Blair reiterated a “market perform” rating on shares of Maravai LifeSciences in a research report on Friday, November 8th. Royal Bank of Canada cut their price objective on Maravai LifeSciences from $17.00 to $13.00 and set an “outperform” rating for the company in a research report on Friday, November 8th. Wolfe Research assumed coverage on Maravai LifeSciences in a research report on Thursday, November 14th. They set a “peer perform” rating on the stock. Finally, The Goldman Sachs Group lowered shares of Maravai LifeSciences from a “neutral” rating to a “sell” rating and cut their price target for the stock from $7.00 to $4.25 in a report on Thursday, December 5th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $10.32.

Maravai LifeSciences Price Performance

The company has a 50-day moving average of $5.03 and a 200 day moving average of $6.61. The company has a quick ratio of 9.94, a current ratio of 10.74 and a debt-to-equity ratio of 0.89. The stock has a market capitalization of $1.01 billion, a PE ratio of -2.45 and a beta of -0.08.

Insider Transactions at Maravai LifeSciences

In other news, General Counsel Kurt Oreshack sold 25,000 shares of the firm’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $5.03, for a total value of $125,750.00. Following the transaction, the general counsel now directly owns 167,618 shares of the company’s stock, valued at approximately $843,118.54. This trade represents a 12.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders own 0.63% of the company’s stock.

Institutional Trading of Maravai LifeSciences

Several large investors have recently bought and sold shares of MRVI. Creative Planning boosted its holdings in shares of Maravai LifeSciences by 4.4% during the 3rd quarter. Creative Planning now owns 44,943 shares of the company’s stock worth $373,000 after purchasing an additional 1,881 shares during the last quarter. Blue Trust Inc. boosted its stake in Maravai LifeSciences by 181.1% during the third quarter. Blue Trust Inc. now owns 17,409 shares of the company’s stock worth $145,000 after buying an additional 11,215 shares during the last quarter. Custom Index Systems LLC purchased a new stake in Maravai LifeSciences in the 3rd quarter valued at $97,000. China Universal Asset Management Co. Ltd. grew its holdings in Maravai LifeSciences by 74.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 27,225 shares of the company’s stock valued at $226,000 after buying an additional 11,621 shares in the last quarter. Finally, Cannon Global Investment Management LLC acquired a new stake in shares of Maravai LifeSciences in the 3rd quarter worth $590,000. Hedge funds and other institutional investors own 50.25% of the company’s stock.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.